S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:BLFS

BioLife Solutions - BLFS Stock Forecast, Price & News

$20.35
-0.91 (-4.28%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$20.11
$21.38
50-Day Range
$12.99
$21.49
52-Week Range
$10.40
$60.67
Volume
432,661 shs
Average Volume
417,940 shs
Market Capitalization
$863.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.17

BioLife Solutions MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
107.2% Upside
$42.17 Price Target
Short Interest
Bearish
5.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.52mentions of BioLife Solutions in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$325,403 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.67) to ($0.18) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

565th out of 1,098 stocks

Electromedical Equipment Industry

13th out of 23 stocks

BLFS stock logo

About BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on BLFS. Cowen decreased their price objective on shares of BioLife Solutions from $50.00 to $32.00 in a report on Tuesday, May 10th. TheStreet downgraded shares of BioLife Solutions from a "c-" rating to a "d" rating in a research report on Tuesday, April 12th. B. Riley cut their target price on shares of BioLife Solutions from $48.00 to $34.00 in a research report on Tuesday, May 17th. Oppenheimer raised shares of BioLife Solutions from a "market perform" rating to an "outperform" rating in a research report on Monday, April 25th. Finally, Cowen cut their target price on shares of BioLife Solutions from $50.00 to $32.00 in a research report on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $42.17.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock opened at $21.26 on Tuesday. The firm's 50 day moving average price is $16.07 and its 200-day moving average price is $18.80. The company has a quick ratio of 2.53, a current ratio of 3.39 and a debt-to-equity ratio of 0.01. BioLife Solutions has a 52-week low of $10.40 and a 52-week high of $60.67.

BioLife Solutions (NASDAQ:BLFS - Get Rating) last issued its quarterly earnings data on Monday, May 9th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.06). The firm had revenue of $36.22 million during the quarter, compared to analysts' expectations of $37.87 million. BioLife Solutions had a negative return on equity of 6.24% and a negative net margin of 10.35%. During the same period in the previous year, the firm earned $0.01 EPS. As a group, sell-side analysts predict that BioLife Solutions will post -0.67 EPS for the current year.

Insider Buying and Selling

In related news, CRO Marcus Schulz sold 4,600 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $20.03, for a total value of $92,138.00. Following the completion of the sale, the executive now directly owns 36,218 shares in the company, valued at approximately $725,446.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CRO Marcus Schulz sold 4,600 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $20.03, for a total value of $92,138.00. Following the completion of the sale, the executive now directly owns 36,218 shares in the company, valued at approximately $725,446.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Greef Roderick De sold 9,158 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, July 12th. The stock was sold at an average price of $15.79, for a total transaction of $144,604.82. Following the completion of the sale, the chief operating officer now owns 124,458 shares of the company's stock, valued at $1,965,191.82. The disclosure for this sale can be found here. Insiders sold 19,678 shares of company stock worth $325,403 in the last three months. Corporate insiders own 3.30% of the company's stock.

Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Stock News Headlines

BioLife Solutions (BLFS) Scheduled to Post Earnings on Tuesday
BioLife Solutions Inc. News
BioLife Solutions, Inc. (BLFS)
BioLife Solutions Tops Q1 EPS by 8c
BioLife Solutions Q4 2021 Earnings Preview
See More Headlines
Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Company Calendar

Last Earnings
11/11/2021
Today
8/09/2022
Next Earnings (Confirmed)
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLFS
Employees
432
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$42.17
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+107.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-7,640,000.00
Pretax Margin
-24.76%

Debt

Sales & Book Value

Annual Sales
$119.16 million
Book Value
$11.80 per share

Miscellaneous

Free Float
41,010,000
Market Cap
$863.04 million
Optionable
Not Optionable
Beta
1.99














BLFS Stock - Frequently Asked Questions

Should I buy or sell BioLife Solutions stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings
or view top-rated stocks.

What is BioLife Solutions' stock price forecast for 2022?

6 Wall Street research analysts have issued 12 month price objectives for BioLife Solutions' shares. Their BLFS share price forecasts range from $30.00 to $65.00. On average, they anticipate the company's stock price to reach $42.17 in the next year. This suggests a possible upside of 105.0% from the stock's current price.
View analysts price targets for BLFS
or view top-rated stocks among Wall Street analysts.

How has BioLife Solutions' stock price performed in 2022?

BioLife Solutions' stock was trading at $37.27 at the start of the year. Since then, BLFS stock has decreased by 44.8% and is now trading at $20.57.
View the best growth stocks for 2022 here
.

When is BioLife Solutions' next earnings date?

BioLife Solutions is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our BLFS earnings forecast
.

How can I listen to BioLife Solutions' earnings call?

BioLife Solutions will be holding an earnings conference call on Tuesday, August 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) released its earnings results on Thursday, November, 11th. The medical equipment provider reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by $0.21. The medical equipment provider had revenue of $33.80 million for the quarter, compared to analysts' expectations of $31.65 million. BioLife Solutions had a negative trailing twelve-month return on equity of 6.24% and a negative net margin of 10.35%. During the same quarter in the previous year, the company earned ($0.02) EPS.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions updated its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $159.50 million-$171.00 million, compared to the consensus revenue estimate of $165.38 million.

What is Mike Rice's approval rating as BioLife Solutions' CEO?

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by many different retail and institutional investors. Top institutional investors include Geneva Capital Management LLC (3.43%), Gagnon Securities LLC (1.35%), TimesSquare Capital Management LLC (1.15%), Zweig DiMenna Associates LLC (1.10%), Jennison Associates LLC (1.08%) and RMB Capital Management LLC (0.83%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Thomas Girschweiler, Todd Berard, Troy Wichterman and Walter Villiger.
View institutional ownership trends
.

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $20.57.

How much money does BioLife Solutions make?

BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $872.37 million and generates $119.16 million in revenue each year. The medical equipment provider earns $-7,640,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does BioLife Solutions have?

BioLife Solutions employs 432 workers across the globe.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433.

This page (NASDAQ:BLFS) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.